Research Symposium

&

The Pam and Rolando Del Maestro Family
Undergraduate Student Research Competition Awards

**Please note:** Undergraduate students wishing to compete in competition are encouraged to apply from anywhere in Canada. If selected to compete and not able to attend in person, teams will be streamed in.

Saturday, September 15, 2018
9:30 am - 12:30 pm
London, ON
First, Second and Third place winners in this competition will be invited to compete in final competition in Toronto, ON, Saturday October 20, 2018 at our Brain Tumour National Conference.
Prizes in final three has monetary value

In 2017, The Pam And Rolando Del Maestro Family Undergraduate Student Research Competition Awards were established to promote scientific innovation among Canadian undergraduate students.

35 years ago, Pam and Rolando Del Maestro co-founded Brain Tumour Foundation of Canada and over the years have fostered students in the field of brain tumour research by providing them with varied opportunities to present their ideas and engage with physicians and researchers in the field of neuro-oncology and neuroscience.

Brain Tumour Foundation of Canada thanks our co-founders Pam and Rolando Del Maestro for establishing this visionary opportunity.
Overview:
This undergraduate research competition is to showcase work to other scientists, researchers and professionals attending Research Symposium. Top 3 winning teams receive the opportunity to present at our Brain Tumour National Conference in October and compete for monetary prizes. Presentations will be relevant to the brain tumour research community. Its purpose will be to provide students an opportunity to create a research proposal, practice presentation skills and receive constructive feedback from a panel that will include physicians and researchers. This competition allows students to network and create awareness while engaging the brain tumour community in brain tumour research.

Process:
Brain Tumour Foundation of Canada’s Research Committee has created a standardized clinical case study relevant to brain tumours. A letter of intent to participate is due no later than Friday August 3, 2018 at 4:30 pm (EST).

Those participating will be asked to work in groups ranging from 2-4 group members. Grant proposals will be assessed via a two-step mechanism by the judging committee.

1) Letter of Intent- Please follow below format **DUE:** Friday August 3, 2018
The Letter of Intent (LOI) must include the following:

- **Background of the field**
  - Describe any background information on research topic. This must include key principles to understand proposal

- **Research problem**
  - This should clearly state an unresolved concern in the scholarly literature that needs to be improved or eliminated. The significance of your proposal should be illustrated here

- **Hypothesis**
  - State the hypothesis of the proposed study in the context of the research problem

- **Specific aims**
  - Present up to three specific aims. These should be the narrower and more specific objectives of the proposed study in relation to the hypothesis. Under each specific aim, elaborate on the methodologies. Where applicable, describe theoretical results.

- **Methodologies**
  - This section should elaborate on the experimental procedures that will allow any other scientist to replicate your experiments. Data collection and analysis protocol must be included.

- **Hypothesized results**

- **Rationale for proposed research/therapeutic relevance**
  - The following questions should be addressed in this section: How is the proposed study innovative and supportive on the goals of brain tumour
research? Why should this project be done? How is it therapeutically relevant?
- Key references
  - Maximum of 30 references

Additional Information:
- All necessary information above required
- Letters of Intent should be no more than 2 pages single spaced.
- Font should be Arial and at least 12 points
- To submit your Letter of Intent, please email as a PDF attachment to sruypers@braintumour.ca

**Deadline:** Friday August 3, 2018
**Results to be provided by:** August 17, 2018
(all those who submitted LOI’s will be notified regardless of results)

2) **Oral Presentation**

After reviewing the full research grant applications, teams will be invited to deliver an oral presentation to the selection committee at the Brain Tumour Foundation of Canada Research Symposium on **Saturday September 15, 2018**.

Participants will be given the opportunity to select their own specific topic of interest and be encouraged to form a research proposal that is experimental and not an observational study nor a clinical survey.

Visual Aids (i.e. illustrative slides) should be used were possible to make the presentation easy for judges and the audience to understand the research proposed. Presentations will be scored based on the how well the panel of judges believes your presentation meets each of the above criteria.

**NOTE:** Please respect copyright and academic citation standards when using images and data from text books and academic journals.

**What we do not expect:**
The goal for this competition is not “ready for the lab projects.”
The competition is not meant to be based on student thesis projects.
The basic idea is “If you were attempting to get funding for a whole project what would you present to a panel of scientists to convince them?”

**Possible Topics**

**Surgery**

Recent evidence casts doubt on whole brain radiation therapy as a main treatment option for brain metastases. Tumour bed directed stereotactic surgery may be a promising alternative for its localized therapy approach.
Endoscopic procedures permit precise observation of the surface of the tumour while avoiding vessels during resections, creating the possibility for almost complete resections of deep-seated tumours.

Pharmacology
Systemic drug therapy is a management option for meningioma that cannot be completely resected. Antiangiogenic agents that interfere with tumour-induced angiogenesis may serve as rational novel treatments in such cases.

The blood-brain barrier hinders drug delivery to the brain due to its selective nature. Increasing the blood-brain barrier permeability without disturbing other brain cells can be an innovative approach to increasing the success of targeted cancer therapies.

Palliative & End-of-Life Care
Discussing palliative and end-of-life care with parents of children with a brain tumour remains a challenge to healthcare providers. This study examines training procedures to prepare medical professionals to deliver Communication Plan: Early Through End of Life (COMPLETE) intervention to parents.

Stem Cells
One emerging topic of research focuses on cancer stem cells that may contribute to tumour growth via their self-renewal capacity. Therapies that selectively target cancer stem cells may help eradicate cancer and prevent reoccurrence.

Patient Selection
Responses to one treatment may vary from patient to patient. For instance, age can largely influence treatment consequences for patients with medulloblastoma. Novel methods of risk stratification will be necessary to personalize approaches to medulloblastoma per case.

Molecular Biology
MicroRNAs are implicated in the regulation of gene expression at the post-transcriptional level. It is hypothesized that they may alter key tumour suppressor activity to result in brain cancer development. MicroRNAs may thus be potential biomarkers and/or therapeutic targets for embryonal tumours.

For more info:
http://www.ncbi.nlm.nih.gov.libaccess.lib.mcmaster.ca/pmc/articles/PMC4264241/

Day of Conference:

Day of Conference, each team will be provided 8 minutes to present proposals with 5 minutes of feedback. Three winning teams will be selected at the end of the competition who will be invited to present at our JTM Conference on Saturday October 20, 2018 from 10:30-11:15am. Rankings are based on presentation performance and content of abstract and full proposal scores previously earned.

Certificates will be provided to all participating teams and local winners will be announced from 1st-3rd place.

Winning teams will have the opportunity to compete in the final 3 across Canada with prize values available below.

1st Place- $1000
2nd Place- $750
3rd Place- $500

Ranking Committee/Case Study Development: TBA

Moderator of Event: Sue Ruypers

Case Study:

Connie is a 40 year old physiotherapist who presented with a generalized seizure. On examination in the emergency room she had some moderate left-sided weakness. The emergency room doctor ordered a computerized axial tomography (CT) scan of the head which was abnormal. She was started on medication for her seizure and the weakness resolved over the following week. She then went on to have magnetic resonance imaging (MRI) of the head which better defined the abnormality: a right frontal brain lesion. Connie was referred to a neurosurgeon. Connie and her family met with the neurosurgeon and there was discussion about the possible radiological diagnoses. Management options were discussed. The neurosurgeon gave Connie the Brain Tumour Foundation of Canada Handbook on brain tumours and after discussion with her family Connie opted for resection of the brain lesion. Two days later Connie underwent a craniotomy and resection of the brain lesion (under neuroleptic anesthesia) and a piece
was sent for pathological analysis. The neuropathologist reported that the lesion was a brain tumour called a diffuse astrocytoma and Connie was informed. A week after the surgery, Connie and her family met with the neurosurgeon, neuro-oncologist and radiation oncologist to discuss the next steps.

Connie and her family had the following questions/concerns, having already searched the Internet:

1. What is the next best step for management of this diffuse astrocytoma – more surgery, chemotherapy, radiation therapy or some combination? What is the supporting evidence?
2. According to the Internet certain factors might impact how Connie responds to treatment. What are these factors and what is their relative importance? What is being done to identify other factors?
3. Connie and her family wanted to know if there were any experimental therapies for a patient with this kind of brain tumour. They wanted to know what a clinical trial was and if there might be any current clinical trials for which she might be eligible.
4. Connie is concerned that his having a brain tumour is going to negatively impact her quality of life. She wants to know if there is any evidence to support his concern and, if so, is there anything being done to minimize this. Connie also wants to know if anything is being done to help families optimally deal with a family member with a brain tumour.

The Brain Tumour Foundation of Canada is inviting students to devise a proposal for scientific research that addresses one or more of the above issues surrounding Connie’s brain tumour (diffuse astrocytoma).